Treatment of angina pectoris and hypertension with sustained-release calcium channel-blocking drugs.
Sustained-release diltiazem (D-SR) and sustained-release verapamil (V-SR) when given twice a day have been successfully used to treat both essential hypertension and angina pectoris. Review of available studies indicates that 120 to 180 mg D-SR twice a day and 240 mg V-SR once or twice a day can lower diastolic pressure in 40% to 80% of patients with essential hypertension and that the drugs may be especially useful in patients with low-renin hypertension such as elderly and black populations. D-SR and V-SR prolong treadmill capacity and reduce frequency of angina in patients with stable effort angina. Improvement is mediated primarily by a reduction in resting and submaximal exercise heart rate. Biopharmaceutics of D-SR and V-SR feature a prolonged apparent plasma half-life and reduced peak-to-trough plasma concentration ratios during steady-state dosing.
D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy*; D001682:Biological Availability; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000008:administration & dosage / Q000097:blood; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D014700:Verapamil / Q000008:administration & dosage / Q000097:blood
D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D006852:Hydrochlorothiazide; D014700:Verapamil; D004110:Diltiazem